Tripos releases new version of SYBYL-X for QSAR studies

Tripos^®, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.2. This new release focuses on streamlined workflows for life science researchers, with the addition of a new, project-oriented interface for QSAR studies, from obtaining data to delivering findings, suitable for the QSAR novice and expert alike. Additionally, researchers benefit from improvements to docking with the addition of Surflex-Dock's fragment-constrained docking and treatment of protein flexibility.

Tripos' SYBYL-X product manager and lead scientist, Brian B. Masek, Ph.D., said, "Tripos has been the industry leader in 3D QSAR since the inception of Comparative Molecular Field Analysis (CoMFA), which is cited in literally thousands of peer-reviewed research publications, and we've continued at the forefront of 3D QSAR science with the recent release of the next generation of 3D QSAR, with Topomer CoMFA, allowing 3D QSAR predictions to be used for R-group virtual screening."

According to Dr. Masek, "The introduction of the new QSAR project manager really brings accessibility of CoMFA to a new level, simplifying the entire workflow from structure preparation and training/test set selection all the way through to delivering results. Customers are very excited, reporting that using the new project manager, they have much higher reproducibility and interpretation of experiments started or run days or even months earlier, and that the packaging and structuring of the workflow really makes them more productive. Additionally, the docking enhancements allow scientists to more closely approximate real-world conditions with the addition of treatment of protein flexibility, and to use known information about particular fragment placement to guide docking."

The breadth and depth of scientific application in SYBYL-X remains unrivaled, with emphasis on lead identification and optimization, and including capabilities for cheminformatics, and small molecule as well as macromolecule modeling and simulation.

According to Patrick Flanagan, Tripos' Chief Operating Officer, "Tripos continues to innovate scientifically, and to invest in workflow improvements that will help scientists be more productive than ever in today's competitive environment. Our continued focus on providing easier ways to access the well-validated, robust science offered in SYBYL-X, coupled with the simplicity of purchasing options and single price point for the entire suite, combine to make SYBYL-X the most affordable, cost-effective life science molecular modeling solution available today. "